Patient Characteristics
. | Number . |
---|---|
Total no. pts. | 56 |
Age (median) | 29.5 yr (range 18 to 56) |
Male | 26 |
Female | 30 |
B symptoms at relapse | |
No | 35 |
Yes | 21 |
Stage at relapse | |
I* | 6 |
II* | 13 |
III† | 9 |
IV† | 28 |
Extranodal sites at relapse | |
0 | 26 |
1 | 19 |
2 | 9 |
3 | 1 |
4 | 1 |
Histology | |
Nodular sclerosis | 48 |
Mixed cellularity | 7 |
Lymphocyte depletion | 1 |
Prior treatments | |
MOPP | 5 |
ABVD | 6 |
MOPP/ABV, MOPP/ABVD or CVPP/ABDIC | 45 |
Disease status | |
Primary refractory (<PR) | 7 |
PR | 6 |
First relapse | 33 |
Second relapse | 10 |
Response duration | |
<12 mo | 33 |
≥12 mo | 23 |
. | Number . |
---|---|
Total no. pts. | 56 |
Age (median) | 29.5 yr (range 18 to 56) |
Male | 26 |
Female | 30 |
B symptoms at relapse | |
No | 35 |
Yes | 21 |
Stage at relapse | |
I* | 6 |
II* | 13 |
III† | 9 |
IV† | 28 |
Extranodal sites at relapse | |
0 | 26 |
1 | 19 |
2 | 9 |
3 | 1 |
4 | 1 |
Histology | |
Nodular sclerosis | 48 |
Mixed cellularity | 7 |
Lymphocyte depletion | 1 |
Prior treatments | |
MOPP | 5 |
ABVD | 6 |
MOPP/ABV, MOPP/ABVD or CVPP/ABDIC | 45 |
Disease status | |
Primary refractory (<PR) | 7 |
PR | 6 |
First relapse | 33 |
Second relapse | 10 |
Response duration | |
<12 mo | 33 |
≥12 mo | 23 |